Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM. Juvekar A, et al. Among authors: nardella c. Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22. Cancer Discov. 2012. PMID: 22915751 Free PMC article.
The APL paradigm and the "co-clinical trial" project.
Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. Nardella C, et al. Cancer Discov. 2011 Jul;1(2):108-16. doi: 10.1158/2159-8290.CD-11-0061. Cancer Discov. 2011. PMID: 22116793 Free PMC article. Review.
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. González-Billalabeitia E, et al. Among authors: nardella c. Cancer Discov. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27. Cancer Discov. 2014. PMID: 24866151 Free PMC article.
Pro-senescence therapy for cancer treatment.
Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Nardella C, et al. Nat Rev Cancer. 2011 Jun 24;11(7):503-11. doi: 10.1038/nrc3057. Nat Rev Cancer. 2011. PMID: 21701512 Review.
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, Pandolfi PP. Lunardi A, et al. Among authors: nardella c. Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4. Cancer Discov. 2015. PMID: 25653093 Free PMC article.
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. Lunardi A, et al. Among authors: nardella c. Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2. Nat Genet. 2013. PMID: 23727860 Free PMC article.
70 results